Innovent Biologics, Inc. (HKG:1801)
Hong Kong · Delayed Price · Currency is HKD 85.50
+6.10 (7.68%)
At close: Mar 27, 2026
Innovent Biologics Revenue
In the year 2025, Innovent Biologics had annual revenue of 13.04B CNY with 38.42% growth. Innovent Biologics had revenue of 7.09B in the half year ending December 31, 2025, with 102.26% growth.
Revenue
13.04B CNY
Revenue Growth
+38.42%
P/S Ratio
10.22
Revenue / Employee
1.74M CNY
Employees
7,502
Market Cap
148.36B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 13.04B | 3.62B | 38.42% |
| Dec 31, 2024 | 9.42B | 3.22B | 51.82% |
| Dec 31, 2023 | 6.21B | 1.65B | 36.21% |
| Dec 31, 2022 | 4.56B | 286.65M | 6.71% |
| Dec 31, 2021 | 4.27B | 425.91M | 11.08% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines AG | 41.59B |
| Sino Biopharmaceutical | 35.43B |
| WuXi Biologics | 24.25B |
| 3SBio | 9.94B |
| Shanghai Henlius Biotech | 7.42B |
| RemeGen | 3.62B |
| Akeso | 3.40B |
| Shanghai Junshi Biosciences | 2.78B |
Innovent Biologics News
- 3 days ago - Innovent Announces 2025 Annual Results and Business Updates - PRNewsWire
- 5 days ago - Innovent Biologics Phase 3 STAR Study Shows Efdamrofusp Alfa Effective In NAMD - Nasdaq
- 6 days ago - Innovent Announces First Participant Dosed of IBI128 (Tigulixostat, XOI) in Phase 3 Clinical Study - PRNewsWire
- 4 weeks ago - Hong Kong-listed Chinese drug firms set to turn corner on rising sales, licensing deals - South China Morning Post
- 6 weeks ago - Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for First Line Treatment of HER2-positive Breast Cancer - PRNewsWire
- 6 weeks ago - Innovent Biologics Strikes Partnership Deal With Eli Lilly - WSJ
- 6 weeks ago - China's Innovent clinches new Lilly deal for immunology, cancer drug development - Reuters
- 7 weeks ago - Innovent Announces Strategic Collaboration with Lilly to Develop New Medicines Globally in Oncology and Immunology - PRNewsWire